Trevena, Inc. (NASDAQ:TRVN – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.01 and traded as low as $0.0010. Trevena shares last traded at $0.0010, with a volume of 109 shares traded.
Trevena Price Performance
The company’s fifty day simple moving average is $0.01 and its 200-day simple moving average is $0.01. The firm has a market capitalization of $959.00, a PE ratio of -0.00 and a beta of -0.44.
About Trevena
Trevena, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligand G protein-coupled receptor (GPCR) selective medicines. By leveraging its proprietary bias-ligand technology platform, Trevena aims to create therapies that preferentially activate beneficial signaling pathways while minimizing engagement of pathways linked to adverse effects. The company’s research efforts target areas of high unmet medical need, including pain management, cardiometabolic disorders and central nervous system conditions.
The company’s lead compound, oliceridine (also known by its brand name OLINVEO), is a G protein-biased μ-opioid receptor agonist designed for the treatment of moderate to severe acute pain in the hospital setting.
Further Reading
- Five stocks we like better than Trevena
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
